Authors
Loading...
Preclinical analysis demonstrates that LILRB4 promotes multiple myeloma growth via STAT3-PFKFB1 signaling, suggesting a viable target for immunotherapy-resistant disease.
Xie et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: